Biomarker ID | 702 |
PMID | 21822036 |
Year | 2011 |
Biomarker | Methylation Status of (RARB or GSTP1 or RASSF1) |
Biomarker Basis | Methylation Based |
Biomolecule | Methylation |
Source | Urine |
Subjects | Humans |
Regulation | Hypermethylated in Cancer |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways include (GSTP1): Biological oxidations, Metapathway biotransformation, Pathways in cancer, T cell receptor regulation of apoptosis, Metabolism Pathways Include(RARB):-Non-small cell lung cancer,Vitamin A and carotenoid metabolism,Nuclear receptor transcription pathway,Nuclear receptors,Small cell lung cancer Pathways Include(RASSF1):- Bladder cancer, Non-small cell lung cancer, p53 activity regulation, Pathways in cancer |
Experiment | Methylation in Patients with PCa |
Type of Biomarker | Prognostic |
Cohort | 34 patients with untreated prostate cacner were selected, The cases were diagnosed with early- (pT2, n=21) or medium-stage (pT3, n=13) prostate carcinoma of score 6 (n=24) or 7 (n=10). |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | 82% |
Level Of Significance | NA |
Method Used | Real-time methylation-specific PCR |
Clinical | No |
Remarks | The frequencies of aberrant promoter methylation for RASSF1, RARB, and GSTP1 were 71% (24 of 34), 44% (15 of 34), and 3% (1 of 34), respectively. |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | RARB, GSTP1, RASSF1 |